Brain Navi Biotechnology Co., Ltd.: TFDA Approves the First

HSINCHU, Aug. 8, 2022 /PRNewswire/ -- NaoTrac, the CE-certified neurosurgical navigation robot, achieved approval from Taiwan's Food and Drug Administration (TFDA) in July 2022, and is planned

Related Keywords

Taiwan , Hualien , Hualian Xian , Washington , United States , San Francisco , California , Taiwanese , Kostenloser Wertpapierhandel , Acta Neurochirurgica , Prnewswire Naotrac , Surface Mapping Technology , Hualien Tzu Chi Medical Center , Registration Technology , Drug Administration , External Ventricular Drain , Surface Mapping Auto Registration Technology , Taiwan Expo United States , Navi Biotechnology , Brain , Avi , Biotechnology , Fda , Pproves , First , Utonomous , Neurosurgical , Navigation , Robot , Aotrac , Rom ,